STOCK TITAN
  1. Home
  2. Sec-filings
  3. TNYA
  4. [Form 4] Tenaya Therapeutics, Inc. Insider Trading Activity

Form 4: Ali Faraz reports sale transactions in TNYA

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Ali Faraz reported open-market sale transactions in a Form 4 filing for TNYA. The filing lists transactions totaling 14,862 shares at a weighted average price of $0.64 per share. Following the reported transactions, holdings were 452,415 shares.

Positive

  • None.

Negative

  • None.

Insights

CEO Ali Faraz’s reported sales are small, routine tax-withholding transactions tied to RSU vesting.

The filing shows three open-market sales of Tenaya Therapeutics common stock on February 17, 2026, in amounts of 5,851, 3,979 and 5,032 shares, at weighted average prices around $0.64 per share. The transaction code is S, which denotes a sale.

Footnotes clarify these shares were sold specifically to cover tax withholding on restricted stock units granted in 2023, 2024, and 2025, rather than discretionary selling. After these sales, Ali Faraz beneficially owned 443,404 shares, including 330,187 shares that will be issued upon future RSU vesting.

Because the filing ties the activity to standard equity-compensation taxation, not a large discretionary reduction in exposure, it is best viewed as an administrative equity event. Future company filings may detail additional RSU vesting or insider transactions if they occur.

Insider Ali Faraz
Role Chief Executive Officer
Sold 14,862 shs ($10K)
Type Security Shares Price Value
Sale Common Stock 5,851 $0.643 $4K
Sale Common Stock 3,979 $0.6431 $3K
Sale Common Stock 5,032 $0.643 $3K
Holdings After Transaction: Common Stock — 452,415 shares (Direct)
Footnotes (1)
  1. Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023. Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.6075 to $0.671. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Includes 354,250 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 23, 2024. Includes 343,625 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 6, 2025. Includes 330,187 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ali Faraz
(Last) (First) (Middle)
C/O TENAYA THERAPEUTICS, INC.
171 OYSTER POINT BLVD., 5TH FLOOR
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Tenaya Therapeutics, Inc. [ TNYA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/17/2026 S(1) 5,851 D $0.643(2) 452,415(3) D
Common Stock 02/17/2026 S(4) 3,979 D $0.6431(2) 448,436(5) D
Common Stock 02/17/2026 S(6) 5,032 D $0.643(2) 443,404(7) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023.
2. Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.6075 to $0.671. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
3. Includes 354,250 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
4. Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 23, 2024.
5. Includes 343,625 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
6. Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 6, 2025.
7. Includes 330,187 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
/s/ Jennifer Drimmer Rokovich, Attorney-in-Fact 02/17/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider stock transaction did Tenaya Therapeutics (TNYA) report for CEO Ali Faraz?

Tenaya Therapeutics reported that CEO Ali Faraz sold several small blocks of common stock on February 17, 2026. The filing shows three sales linked to equity awards, each disclosed with exact share counts, prices, and updated beneficial ownership following the transactions, as required for insider reporting.

How many Tenaya Therapeutics (TNYA) shares did CEO Ali Faraz sell and at what prices?

Ali Faraz sold 5,851, 3,979 and 5,032 Tenaya Therapeutics common shares on February 17, 2026. The weighted average sale prices were about $0.643 and $0.6431 per share, with transactions executed across multiple trades within a price range from $0.6075 to $0.671.

Why did Tenaya Therapeutics (TNYA) CEO Ali Faraz sell shares in this Form 4 filing?

The shares were sold to cover tax withholding obligations arising from vesting restricted stock units. Footnotes explain each sale corresponds to RSU awards granted in 2023, 2024, and 2025, making these transactions routine equity-compensation related events rather than discretionary portfolio rebalancing by the CEO.

How many Tenaya Therapeutics (TNYA) shares does CEO Ali Faraz own after these transactions?

After the reported transactions, Ali Faraz beneficially owned 443,404 shares of Tenaya Therapeutics common stock. This figure includes 330,187 shares that will be issued upon vesting of restricted stock units, meaning part of his reported stake consists of unvested equity awards scheduled to settle in shares later.

What do the footnotes reveal about Ali Faraz’s Tenaya Therapeutics (TNYA) equity awards?

The footnotes show that Faraz holds significant restricted stock unit grants scheduled to convert into common stock upon vesting. Specifically, they note 354,250, 343,625 and 330,187 shares tied to RSU awards from 2023, 2024 and 2025, illustrating ongoing equity-based compensation that increases his potential future share ownership.